BMO Capital Markets affirmed their positive stance on Novo Nordisk (NYSE:NVO) shares, maintaining an Outperform rating and a $105.00 price target. This confirmation followed the U.S. Food and Drug ...

NEW YORK, NY / ACCESS Newswire / January 28, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of ...

Novo Nordisk (NVO) announced that the Food and Drug Administration has approved Ozempic to reduce the risk of kidney disease worsening, kidney ...

Here are some of the major companies whose stocks moved on the week’s news.

Novo Nordisk stock is paring its year-over-year deficit on positive early stage trial results for the company's new weight ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for ...

Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...